布地奈德联合肺力咳治疗小儿哮喘

Budesonide Combined with Feilike Treatment in Clinical Effect of Pediatric Asthma

目的:探讨布地奈德联合肺力咳治疗小儿哮喘的临床效果。方法:对来本院诊治的80例患者入院资料进行分析,将其随机分为两组。对照组采用布地奈德混悬液治疗,实验组联合肺力咳治疗,比较两组治疗效果。结果:实验组95%治疗效果理想,高于对照组(80%)(P<0.05);实验组95%对本院治疗总体满意,高于对照组(P<0.05);实验组咳嗽缓解时间为(4.35±1.25)d,咳嗽消失时间为(8.99±2.17)d,平均治疗时间为(17.12±1.5)d,低于对照组(P<0.05);实验组治疗后一秒用力呼气容积(forced expiratory volume in one second,FEV1)指标为(1.57±0.31)L、峰值呼气流速(PEF)为(3.82±0.37)L,FEV1/用力肺活量(FVC)指标为(83.54±0.62)%,高于对照组(P<0.05);实验组治疗后3例出现不良反应,不良反应率为7.5%,低于对照组22.5%(9/40)(P<0.05)。结论:文章采用布地奈德联合肺力咳治疗效果理想,能够有效的改善患者症状,值得推广使用。

Objective：To observe the clinical efficacy of Yiqi Tongqiao decoction in the treatment of acute cerebral infarction （ACI）,and determine its effect on serum peroxisome proliferator activated receptor gamma （PPAR-γ） level.Method：Seventy ACI patients were randomly divided into treatment group and observation group.Patients in two groups were given conventional treatment,and patients in the treatment group added Yiqi Tongqiao decoction.The patients in both groups received a 4-week period of treatment.Changes of China stroke scale （CSS） score,clinical symptom score and serum PPAR-γ level were observed before and after treatment.Result：①Thirty patients in both groups completed the study.Clinical efficacy of the treatment group was 86.7%,which was higher than 73.3% of the observation group.②Serum PPAR-γ in patients with ACI was obviously higher than that of the control group （P 〈 0.01）.③After treatment,clinical symptom score,CSS score and serum PPAR-γ level of two groups were significantly decreased （P 〈 0.01）,and the results in treatment group were better than those in the observation group （P 〈 0.01）.④After treatment fasting plasma glucose （FBG）,triglycerides （TG）,total cholesterol （TC） of the treatment group decreased significantly （P 〈 0.01）,while the observation group had no significant change.Conclusion：Using conventional therapy plus Yiqi Tongqiao decoction have remarkable curative effect in treating ACI.Dynamic monitoring serum PPAR-γ level is conducive to assess the effect and progression in treating ACI.